Multifunctional, biocompatible and pH-responsive carbon nanotube- and graphene oxide/tectomer hybrid composites and coatings.

Here we present a route for non-covalent functionalization of carboxylated multi-walled carbon nanotubes and graphene oxide with novel two-dimensional peptide assemblies. We show that self-assembled amino-terminated biantennary and tetraantennary oligoglycine peptides (referred to as tectomers) effectively coat carboxylated multi-walled carbon nanotubes and also strongly interact with graphene oxide due to electrostatic interactions and hydrogen bonding as the driving force, respectively. The resulting hybrids can be made into free-standing conducting composites or applied in the form of thin, pH-switchable bioadhesive coatings onto graphene oxide fibers. Monitoring of cell viability of pancreatic cell lines, seeded on those CNT hybrids, show that they can be used as two- and three-dimensional scaffolds to tissue engineer tumour models for studying ex vivo the tumour development and response to treatment. This highly versatile method in producing pH-responsive hybrids and coatings offers an attractive platform for a variety of biomedical applications and for the development of functional materials such as smart textiles, sensors and bioelectronic devices.

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.

OBJECTIVES: To evaluate the efficacy of orally-administered alendronate compared with intravenously-administered zoledronate. METHODS: This prospective study was carried out at Barts Health HNS Trust between April 2010 and March 2012. This study compares changes in bone mineral density (BMD) in 234 patients treated with 2 bisphosphonates: alendronate taken orally, and zoledronate administered intravenously. One hundred and eighteen patients received alendronate at 70 mg/week, while 116 patients received zoledronate once annually. Dual energy x-ray absorptiometry was used to measure BMD of the left hip and anterior-posterior spine (lumbar L1-L4) skeletal sites at baseline, and at one-, and 2-years post-treatment. RESULTS: This study provides evidence that lumbar spine BMD increased by 3.6% in patients receiving alendronate, and 5.7% in patients receiving zoledronate after 2 years compared with baseline values (p=0.0001 for both). Total hip BMD decreased in patients treated with alendronate by 0.4% but increased in patients receiving zoledronate by 0.8% (p=0.0001). CONCLUSION: This study provides evidence that zoledronate is more effective than alendronate in treating patients with osteoporosis and with no gastrointestinal (GI) serious side effects. Furthermore, zoledronate appears to have the added advantage of a better safety profile in patients suffering from GI intolerance of oral bisphosphonates.

Preliminary Monte Carlo study of (18)F-FDG SPECT imaging with LaBr(3):Ce Crystal-based Gamma Cameras.

The utility of (18)F-deoxyglucose ((18)F-FDG) in oncology, cardiology, and neurology has generated great interest in a more economical ways of imaging (18)F-FDG than conventional PET scanners. The main thrust of this work is to investigate the potential use of LaBr(3):Ce materials in a low-cost FDG-SPECT system compared to NaI(Tl) using GATE Monte Carlo simulation. System performance at 140 keV and 511 keV was assessed using energy spectra, system sensitivity and count rate performance. Comparison of the LaBr(3):Ce and NaI(Tl) crystal-based systems showed 4.5% and 8.9% higher system sensitivity for the LaBr(3):Ce at 140 keV and 511 keV, respectively. The LaBr(3):Ce scintillator significantly improves intrinsic count rate performance due to its fast decay time with respect to NaI(Tl). In conclusion, because LaBr(3):Ce crystal combines excellent intrinsic count rate performance with slightly increased system sensitivity, it has the potential to be used for (18)F-FDG -SPECT systems.